1. An ophthalmic device comprising:
a contact lens requiring rotational stability on an eye, the contact lens having a front curve surface, a back curve surface, an optical zone and a peripheral stabilization zone configured to minimize on eye rotation; and
a multifocus axis component incorporated into at least one of the front curve surface or the back curve surface of the contact lens in the optical zone and having a central disc which includes refractive spherical and cylindrical components at a nominal cylinder axis and a number of alternating concentric annular bands, wherein each band has a different cylindrical axis and which alternate to create a nominal axis meridian, a lower boundary meridian and an upper boundary meridian, wherein the range from the lower boundary meridian to the upper boundary meridian is between +\u22125 degrees to +\u221210 degrees.
2. An ophthalmic device comprising:
a contact lens requiring rotational stability on an eye, the contact lens having a front curve surface, a back curve surface, an optical zone and a peripheral stabilization zone configured to minimize on eye rotation; and
a multifocus axis component incorporated into a least one of the front curve surface or the back curve surface of the contact lens in the optical zone and comprising a nominal axis meridian, a lower boundary axis meridian and an upper boundary axis meridian each defined by a continuous function which varies in amplitude from the contact lens center wherein the range from the lower boundary meridian to the upper boundary meridian is between +\u22125 degrees to +\u221210 degrees.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. A method for inducing analgesia in a subject, said method comprising administering to said subject an effective amount of a compound of formula (I):
wherein each of R1 and R2 is independently selected from a hydrogen atom or a C1-C4alkyl group, R3 and R4 are each hydrogen atoms or together form another chemical bond, each X is independently selected from a hydroxyl group, a halogen atom, a C1-C4alkyl group or a C1-C4alkoxy group, or when two X groups are alkyl or alkoxy groups, they may be connected together to form a ring, and n is an integer from 1 to 3.
2. A method for prophylactically inducing analgesia in a subject, said method comprising administering to said subject an effective amount of a compound of formula (I):
wherein each of R1 and R2 is independently selected from a hydrogen atom or a C1-C4alkyl group, R3 and R4 are each hydrogen atoms or together form another chemical bond, each X is independently selected from a hydroxyl group, a halogen atom, a C1-C4alkyl group or a C1-C4 alkoxy group, or when two X groups are alkyl or alkoxy groups, they may be connected together to form a ring, and n is an integer from 1 to 3.
3. A method for the treatment andor prophylaxis of a condition in a subject, which condition is characterised by symptoms of pain, said method comprising administering to said subject an effective amount of a compound of formula (I):
wherein each of R1 and R2 is independently selected from a hydrogen atom or a C1-C4alkyl group, R3 and R4 are each hydrogen atoms or together form another chemical bond, each X is independently selected from a hydroxyl group, a halogen atom, a C1-C4alkyl group or a C1-C4alkoxy group, or when two X groups are alkyl or alkoxy groups, they may be connected together to form a ring, and n is an integer from 1 to 3, for a time and under conditions sufficient to inhibit or reduce said pain.
4. The method according to claim 1 wherein the carboxyl group is in the 2-, 3- or 4-position of the aromatic ring, at least one of R1 and R2 is a hydrogen atom, R3 and R4 taken together form a chemical bond and n is 1 or 2 and each X, which may be the same or different, is selected from halogen, C1-C4 alkyl or d-C4alkoxy.
5. The method of claim 4 wherein the carboxyl group is in the 2-position, both of R1 and R2 are hydrogen atoms and X is selected from halogen and C1-C4alkoxy and n is 2 and both X are selected from C1-C4alkoxy.
6. The method according to claim 5 wherein said compound is of the formula:
7. The method of claim 6 wherein said compound is selected from the list:
2-3-(2-methylphenyl)-1-oxo-2-propenylaminobenzoic acid;
2-3-(3-methylphenyl)-1-oxo-2-propenylaminobenzoic acid;
2-3-(4-methylphenyl)-1-oxo-2-propenylaminobenzoic acid;
2-3-(2-ethylphenyl)-1-oxo-2-propenylaminobenzoic acid;
2-3-(3-ethylphenyl)-1-oxo-2-propenylaminobenzoic acid;
2-3-(4-ethylphenyl)-1-oxo-2-propenylaminobenzoic acid;
2-3-(2-propylphenyl)-1-oxo-2-propenylaminobenzoic acid;
2-3-(3-propylphenyl)-1-oxo-2-propenylaminobenzoic acid;
2-3-(4-propylphenyl)-1-oxo-2-propenylaminobenzoic acid;
2-3-(2-hydroxyphenyl)-1-oxo-2-propenylaminobenzoic acid;
2-3-(3-hydroxyphenyl)-1-oxo-2-propenylaminobenzoic acid;
2-3-(4-hydroxyphenyl)-1-oxo-2-propenylaminobenzoic acid;
2-3-(2-chlorophenyl)-1-oxo-2-propenylaminobenzoic acid;
2-3-(3-chlorophenyl)-1-oxo-2-propenylaminobenzoic acid;
2-3-(4-chlorophenyl)-1-oxo-2-propenylaminobenzoic acid;
2-3-(2-fluorophenyl)-1-oxo-2-propenylaminobenzoic acid;
2-3-(3-fluorophenyl)-1-oxo-2-propenylaminobenzoic acid;
2-3-(4-fluorophenyl)-1-oxo-2-propenylaminobenzoic acid;
2-3-(2-bromophenyl)-1-oxo-2-propenylaminobenzoic acid;
2-3-(3-bromophenyl)-1-oxo-2-propenylaminobenzoic acid;
2-3-(4-bromophenyl)-1-oxo-2-propenylaminobenzoic acid;
2-3-(2,3-dimethoxyphenyl)-1-oxo-2-propenylaminobenzoic acid;
2-3-(3,4-dimethoxyphenyl)-1-oxo-2-propenylaminobenzoic acid;
2-3-(2,4-dimethoxyphenyl)-1-oxo-2-propenylaminobenzoic acid;
2-3-(2,3-dimethylphenyl)-1-oxo-2-propenylaminobenzoic acid;
2-3-(3,4-dimethylphenyl)-1-oxo-2-propenylaminobenzoic acid;
2-3-(2,4-dimethylphenyl)-1-oxo-2-propenylaminobenzoic acid;
2-3-(2,3-diethoxyphenyl)-1-oxo-2-propenylaminobenzoic acid;
2-3-(3,4-diethoxyphenyl)-1-oxo-2-propenylaminobenzoic acid;
2-3-(2,4-diethoxyphenyl)-1-oxo-2-propenylaminobenzoic acid;
2-3-(2,3-dipropoxyphenyl)-1-oxo-2-propenylaminobenzoic acid;
2-3-(3,4-dipropoxyphenyl)-1-oxo-2-propenylaminobenzoic acid;
2-3-(2,4-dipropoxyphenyl)-1-oxo-2-propenylaminobenzoic acid;
2-3-(2,3-diethylphenyl)-1-oxo-2-propenylaminobenzoic acid;
2-3-(3,4-diethylphenyl)-1-oxo-2-propenylaminobenzoic acid;
2-3-(2,4-diethylphenyl)-1-oxo-2-propenylaminobenzoic acid;
2-3-(2,3-dipropylphenyl)-1-oxo-2-propenylaminobenzoic acid;
2-3-(3,4-dipropylphenyl)-1-oxo-2-propenylaminobenzoic acid;
2-3-(2,4-dipropylphenyl)-1-oxo-2-propenylaminobenzoic acid;
2-3-(2-methoxy-3-methylphenyl)-1-oxo-2-propenylaminobenzoic acid;
2-3-(3-methoxy-4-methylphenyl)-1-oxo-2-propenylaminobenzoic acid;
2-3-(2-methoxy-3-methylphenyl)-1-oxo-2-propenylaminobenzoic acid;
2-3-(2-methoxy-4-methylphenyl)-1-oxo-2-propenylaminobenzoic acid;
2-3-(2-methoxy-3-chlorophenyl)-1-oxo-2-propenylaminobenzoic acid;
2-3-(3-methoxy-4-chlorophenyl)-1-oxo-2-propenylaminobenzoic acid;
2-3-(2-methoxy-3-chlorophenyl)-1-oxo-2-propenylaminobenzoic acid;
2-3-(2-methoxy-4-chlorophenyl)-1-oxo-2-propenylaminobenzoic acid;
2-3-(2-methoxy-3-hydroxyphenyl)-1-oxo-2-propenylaminobenzoic acid;
2-3-(3-methoxy-4-hydroxyphenyl)-1-oxo-2-propenylaminobenzoic acid;
2-3-(2-methoxy-3-hydroxyphenyl)-1-oxo-2-propenylaminobenzoic acid;
2-3-(2-methoxy-4-hydroxyphenyl)-1-oxo-2-propenylaminobenzoic acid;
2-3-(3,4-trimethylenephenyl)-1-oxo-2-propenylaminobenzoic acid;
2-3-(2,3-trimethylenephenyl)-1-oxo-2-propenylaminobenzoic acid;
2-3-(3,4-methylenedioxyphenyl)-1-oxo-2-propenylaminobenzoic acid; and
2-3-(3,4-ethylenedioxyphenyl)-1-oxo-2-propenylaminobenzoic acid.
8. The method according to claim 7 wherein said compound is 2-3-(3,4-dimethoxyphenyl)-1-oxo-2-propenylaminobenzoic acid.
9. The method according to claim 1 wherein said pain is inflammatory pain.
10. The method according to claim 9 wherein said inflammatory pain is associated with cancer, infection, inflammation, autoimmune conditions, AIDS, kidney disease, multiple sclerosis, headache, childbirth, menstruation or a post-operative surgical condition.
11. The method according to claim 10 wherein said autoimmune disorder is rheumatoid arthritis, systemic lupus erythematosus or osteoarthritis.
12. The method according to claim 3 wherein said condition is cancer, infection, inflammation, autoimmune conditions, AIDS, kidney disease, multiple sclerosis, headache, childbirth, menstruation or a post-operative surgical condition.
13. A method of downregulating analgesia in a subject, said method comprising administering to said subject an antagonist of a compound of formula (I) or a pharmaceutically acceptable salt thereof.
14. The method according to claim 1 wherein said subject is a mammal.
15. The method according to claim 14 wherein said mammal is a human.
16. A pharmaceutical formulation comprising
wherein each of R1 and R2 is independently selected from a hydrogen atom or a C1-C4alkyl group, R3 and R4 are each hydrogen atoms or together form another chemical bond, each X is independently selected from a hydroxyl group, a halogen atom, a C1-C4alkyl group or a C1-C4alkoxy group, or when two X groups are alkyl or alkoxy groups, they may be connected together to form a ring, and n is an integer from 1 to 3, in a dose effective to induce analgesia in a mammal.
17-20. (canceled)
21. The pharmaceutical formulation of claim 16 wherein said compound is 2-3-(3,4-dimethoxyphenyl)-1-oxo-2-propenylaminobenzoic acid.
22. The pharmaceutical formulation of claim 16 wherein said pain is inflammatory pain.
23. The pharmaceutical formulation of claim 22 wherein said inflammatory pain is associated with cancer, infection, inflammation, autoimmune conditions, AIDS, kidney disease, multiple sclerosis, headache, childbirth, menstruation or a post-operative surgical condition.
24. The pharmaceutical formulation of claim 23 wherein said autoimmune disorder is rheumatoid arthritis, systemic lupus erythematosus or osteoarthritis.
25-26. (canceled)
27. The pharmaceutical formulation of claim 16 wherein said mammal is a human.